Page 111 - Read Online

Remley et al. Cancer Drug Resist 2023;6:748-67 https://dx.doi.org/10.20517/cdr.2023.63 Page 766

111. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science
2017;357:409-13. DOI PubMed PMC
112. Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015;36:265-76. DOI PubMed
PMC
113. Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov
2014;4:879-88. DOI PubMed
114. Antonioli L, Fornai M, Blandizzi C, Pacher P, Haskó G. Adenosine signaling and the immune system: when a lot could be too much.
Immunol Lett 2019;205:9-15. DOI PubMed
115. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ 2007;14:1315-23.
DOI PubMed
116. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, Enjyoji K. Ectonucleotidases of CD39 family modulate vascular inflammation and
thrombosis in transplantation. Semin Thromb Hemost 2005;31:217-33. DOI
117. Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC. Ecto 5'-nucleotidase and nonspecific alkaline phosphatase. Two AMP-
hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 2003;278:13468-79. DOI PubMed
118. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim
Biophys Acta 2008;1783:673-94. DOI PubMed
119. Mittal D, Sinha D, Barkauskas D, et al. Adenosine 2B receptor expression on cancer cells promotes metastasis. Cancer Res
2016;76:4372-82. DOI
120. Costa A, Kieffer Y, Scholer-Dahirel A, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer.
Cancer Cell 2018;33:463-79.e10. DOI
121. Turcotte M, Spring K, Pommey S, et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res
2015;75:4494-503. DOI
122. Yu M, Guo G, Huang L, et al. CD73 on cancer-associated fibroblasts enhanced by the A -mediated feedforward circuit enforces an
2B
immune checkpoint. Nat Commun 2020;11:515. DOI PubMed PMC
123. Maj T, Wang W, Crespo J, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade
resistance in tumor. Nat Immunol 2017;18:1332-41. DOI PubMed PMC
124. Limagne E, Euvrard R, Thibaudin M, et al. Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer
predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen. Cancer Res 2016;76:5241-52. DOI
125. Chalmin F, Mignot G, Bruchard M, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the
regulation of ectonucleotidase expression. Immunity 2012;36:362-73. DOI
126. Hay CM, Sult E, Huang Q, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology
2016;5:e1208875. DOI PubMed PMC
127. Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol 2016;29:7-16.
DOI PubMed
128. Allard B, Turcotte M, Spring K, Pommey S, Royal I, Stagg J. Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer
2014;134:1466-73. DOI PubMed
129. Feng L, Sun X, Csizmadia E, et al. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular
adenosine triphosphate. Neoplasia 2011;13:206-16. DOI PubMed PMC
130. Jackson SW, Hoshi T, Wu Y, et al. Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am
J Pathol 2007;171:1395-404. DOI PubMed PMC
131. Sun X, Wu Y, Gao W, et al. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor
growth in mice. Gastroenterology 2010;139:1030-40. DOI PubMed PMC
132. Künzli BM, Berberat PO, Giese T, et al. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J
Physiol Gastrointest Liver Physiol 2007;292:G223-30. DOI
133. Zhang B, Cheng B, Li FS, et al. High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma.
Tumour Biol 2015;36:9411-9. DOI
134. Borea PA, Gessi S, Merighi S, Varani K. Adenosine as a multi-signalling guardian angel in human diseases: when, where and how
does it exert its protective effects? Trends Pharmacol Sci 2016;37:419-34. DOI PubMed
135. Huang Y, Gu Z, Fan Y, et al. Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future.
Purinergic Signal 2019;15:53-67. DOI PubMed PMC
136. Vecchio EA, White PJ, May LT. The adenosine A G protein-coupled receptor: recent advances and therapeutic implications.
2B
Pharmacol Ther 2019;198:20-33. DOI PubMed
+
137. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The development and immunosuppressive functions of CD4
+
+
CD25 FoxP3 regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol 2012;3:190.
DOI PubMed PMC
138. Leone RD, Sun IM, Oh MH, et al. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and
improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunol Immunother
2018;67:1271-84. DOI
139. Zarek PE, Huang CT, Lutz ER, et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the